Further pre-clinical and clinical studies will be necessary to determine whether FSHD results from a single dominant pathway modulated by DUX4, or whether it reflects damage from multiple different pathways. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.